Cooperative Agreement UT2AA028659

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $309,974 to support the development of a novel, low-cost device called LIVERscope. The LIVERscope device uses advanced magnetic resonance (MR) technology to noninvasively estimate quantitative biomarkers of nonalcoholic fatty liver disease (NAFLD), including liver...

This National Science Foundation Project Grant of $100,000 supports the development of a self-assembling, protein-based contrast agent targeted to collagen type 1 for non-alcoholic fatty liver disease diagnosis and monitoring. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the award to New York University will support research and innovation leading to a breakthrough biomedical imaging technology. Specifically, the university will develop a recombinant...

The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...

This Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences program supports the development of new classes of magnetic resonance imaging (MRI) contrast agents or probes based on iron coordination complexes. The University of Buffalo's Professor Janet Morrow and her team are working to design iron-based contrast agents that can produce a strong MRI signal. This includes developing both stabilized signal-producing iron agents and oxidation-responsive...

This three-year, $3.13 million project grant from the National Institutes of Health's National Institute of Environmental Health Sciences will fund research at Michigan State University investigating the progression of non-alcoholic fatty liver disease. Specifically, the grant will test the hypothesis that activation of the aryl hydrocarbon receptor by environmental contaminants reprograms fatty acid metabolism, causing the accumulation of toxic lipid intermediates that contribute to...

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $554,188 to The Trustees of the University of Pennsylvania to develop novel silver telluride nanoparticle contrast agents for use in dual-energy mammography breast cancer screening. The goal is to create an improved contrast agent that addresses limitations of current iodine-based agents, providing stronger contrast, a longer imaging window, and better...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $185,171 to The Johns Hopkins University to optimize polymeric chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) agents for prostate cancer detection. The research aims to synthesize and characterize CEST MRI agents with varying charge and...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), is focused on developing iron-based MRI contrast agents as alternatives to gadolinium-based agents. The $305,253 award to Ferric Contrast, Inc. will fund the development and evaluation of iron coordination complexes with macrocyclic ligands to produce stable, water-soluble T1 contrast agents. The research aims to demonstrate enhanced contrast and rapid renal clearance...

This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support research to examine the role of non-parenchymal cells (NPCs) in driving the key features of Alcohol Associated Hepatitis (AAH) in a fully humanized mouse liver model. The $688,199 award to Yale University will fund research over a 5-year period from June 1, 2025 to February 28, 2030. The research aims to elucidate the NPC-derived...